# Pei Kang

> Pei Kang is a seed investor at Chengwei Capital (Shanghai) backing Medical and Genetics. See 4 investments, check sizes, portfolio. Updated Aug 2026.

- Type: Angel Investor
- Fund: [Chengwei Capital](https://shizune.co/investors/profile/chengwei-capital)
- Location: Shanghai, China
- Total investments: 4
- Last investment: Nov 2023
- Lead investor: 50%
- Last updated: Aug 2026
- LinkedIn: http://www.linkedin.com/pub/pei-kang/11/bb6/72a

Pei Kang is a seed investor at Chengwei Capital in Shanghai focused on Medical and Genetics. Mr. Pei Kang serves as the Managing Director of Chengwei Capital. Mr. Kang joined Chengwei Capital in 2003. He serves as Board Observer of Polyera Corporation. He served as Senior Vice President of WK Technology Fund. He led WK's investment activities in China and made several investments in software and manufacturing sectors. Heserved as a Senior Executive at IBM for over 18 years. He served as General Manager of financial service sector in China at IBM. Mr. Kang has been a Director at Huaya Microelectronics, Inc. since December 6, 2004. He served as a Non Executive Director of AAC Technologies Holdings Inc. from February 15, 2007 to May 02, 2010. He holds BS from Chinese Culture University of Taiwan.

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Medical | 1 | 25% |
| Genetics | 1 | 25% |
| Software | 1 | 25% |
| Biopharma | 1 | 25% |
| Automotive | 1 | 25% |

10 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Seed | 1 | 25% |
| Angel | 1 | 25% |
| Series A | 1 | 25% |
| Series C | 1 | 25% |

### Country

| Country | Investments | Share |
| --- | --- | --- |
| China | 2 | 50% |
| United States | 1 | 25% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Jushu Biotech | Jushu Biotech is a medical engineering company that focuses on the research and development of synthetic biosensing technology. | $13.9M | Seed | Nov 17, 2023 |  |
| Jushu Biotech | Jushu Biotech is a medical engineering company that focuses on the research and development of synthetic biosensing technology. | $1.3M | Angel | Jan 13, 2023 |  |
| Raythink Technology | Raythink is committed to the research and development of innovative applications of vehicle-mounted AR display products, providing customers with a highly reusable AR Generator ecological software platform, which enables the vehicle HMI system to continuously embed independent software algorithms/applications, and convert them into AR displaygraphics and visual effects. | $15M | Series A | Jun 07, 2022 |  |
| Polyera | The Polyera Corporation is "a leading supplier in semiconductor, dielectric, and interfacial materials for the printed and flexible electronics industry. Polyera is focused on developing breakthrough materials for its portfolio of ActivInkâ„¢ products and on working closely with customers to provide deep technical support and customizedsolutions in order to enable the commercialization of novel printed and flexible electronic products." |  | Series C | Apr 05, 2012 |  |

4 of 4 investments shown.

## Co-investors
- [3E Bioventures](https://shizune.co/investors/profile/3e-bioventures) — VC Fund, 2 deals together
- [Binhu State Investment](https://shizune.co/investors/profile/binhu-state-investment) — VC Fund, 1 deal together
- [China Unicom](https://shizune.co/investors/profile/china-unicom) — VC Fund, 1 deal together
- [Empower Investment](https://shizune.co/investors/profile/empower-investment) — VC Fund, 1 deal together
- [Solvay](https://shizune.co/investors/profile/solvay) — VC Fund, 1 deal together
- [Tsing Capital](https://shizune.co/investors/profile/tsing-capital) — VC Fund, 1 deal together

## About Chengwei Capital

VC Fund · Shanghai, China

Chengwei Ventures is a venture capital firm.

5 contacts available at Chengwei Capital.

| Name | Title | Profile |
| --- | --- | --- |
| Pei Kang | Managing Director | https://shizune.co/investors/profile/pei-kang |
| Dong Chengxian | Managing Director | https://shizune.co/investors/profile/dong-chengxian |
| Eric X Li | Founder, Managing Director | https://shizune.co/investors/profile/eric-x-li |
| Lou Qun | Managing Director | https://shizune.co/investors/profile/lou-qun |
| Ping Ping | Managing Director | https://shizune.co/investors/profile/ping-ping |

## Similar investors

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [Right Side Capital Management](https://shizune.co/investors/profile/right-side-capital-management) — VC Fund

## FAQ

### What does Pei Kang invest in?

Pei Kang invests primarily in Medical, Genetics and Software startups, most often at Seed and Angel stage. Most of the 4 investments tracked by Shizune back companies in China. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did Pei Kang last invest?

The most recent investment recorded for Pei Kang closed in Nov 2023. Shizune tracks 4 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co